Optodrop (Dorzolamide Hydrochloride)

Dorzolamide Hydrochloride, the active ingredient in Optodrop, is a carbonic anhydrase inhibitor presented as a 0.5% ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Optodrop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Optodrop is a carbonic anhydrase inhibitor used in the management of ocular pressure‑related conditions. - Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic‑nerve damage. - Ocular hypertension: reduces aqueous humor production, decreasing intra‑ocular pressure. - Post‑operative post‑surgical eye care after laser trabeculoplasty or other procedures: assists in maintaining target IOP levels.

Side effects are generally mild and related to the ocular surface, but serious reactions can occur.

Common Side Effects: - Burning or stinging sensation upon instillation. - Transient blurred vision. - Foreign‑body sensation. - Conjunctival hyperemia. - Dry eye sensation. - Mild eye irritation.

Serious or Rare Side Effects: - Allergic contact dermatitis. - Severe ocular inflammation. - Persistent visual acuity loss. - Corneal ulceration. - Acute angle‑closure glaucoma precipitated by misuse. - Systemic metabolic acidosis (very rare).

When using Optodrop, follow these safety considerations: - Avoid contamination: use a new dropper tip after each use. - Monitor IOP: regular intra‑ocular pressure checks are recommended. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Pregnancy and lactation: safety data unknown and should be used only if clearly needed. - Storage: Store at  :   
- . - -   t

The      ...